RenovoRx (RNXT) to Release Earnings on Wednesday

RenovoRx (NASDAQ:RNXT) is anticipated to issue its Q2 2026 results after the market closes on Wednesday, August 12th. Analysts expect RenovoRx to post earnings of ($0.08) per share and revenue of $0.7040 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

RenovoRx (NASDAQ:RNXT) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). The business had revenue of $0.56 million for the quarter, compared to analyst estimates of $0.47 million. RenovoRx had a negative return on equity of 135.03% and a negative net margin of 823.98%. On average, analysts expect RenovoRx to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

RenovoRx Stock Performance

Shares of RNXT stock opened at $1.04 on Wednesday. RenovoRx has a fifty-two week low of $0.70 and a fifty-two week high of $1.45. The firm has a market capitalization of $46.85 million, a PE ratio of -3.15 and a beta of 0.99. The stock’s 50-day simple moving average is $0.91 and its 200-day simple moving average is $0.93.

Wall Street Analyst Weigh In

A number of brokerages recently commented on RNXT. HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of RenovoRx in a research report on Wednesday, April 8th. Wall Street Zen raised shares of RenovoRx from a “strong sell” rating to a “sell” rating in a report on Saturday, July 18th. Ascendiant Capital Markets increased their price objective on shares of RenovoRx from $13.50 to $14.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Finally, Weiss Ratings upgraded shares of RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, RenovoRx currently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Institutional Trading of RenovoRx

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bleichroeder LP raised its position in RenovoRx by 11.4% during the fourth quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock valued at $504,000 after acquiring an additional 61,379 shares in the last quarter. Geode Capital Management LLC boosted its position in RenovoRx by 9.9% in the 2nd quarter. Geode Capital Management LLC now owns 353,603 shares of the company’s stock worth $467,000 after purchasing an additional 31,730 shares in the last quarter. Wealthspire Advisors LLC acquired a new stake in shares of RenovoRx during the 4th quarter worth approximately $212,000. Citadel Advisors LLC purchased a new position in shares of RenovoRx during the 3rd quarter valued at approximately $154,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in shares of RenovoRx in the 2nd quarter valued at $98,000. 3.10% of the stock is owned by institutional investors and hedge funds.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.